Krish Patel, MD

Krish Patel, MD, is director of Lymphoma Research and executive chair of the Lymphoma Research Executive Committee at the Sarah Cannon Research Institute

Articles by Krish Patel, MD

Joanna M. Rhodes, MD, MSCE, director, Lymphoma, systems head, Lymphoma, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health; Krish Patel, MD, director, Lymphoma Research, executive chair, Lymphoma Research Executive Committee, Sarah Cannon Research Institute

CLL Treatment Paradigm Shifts With Evolving Treatment Sequencing and BTK Inhibition: With Joanna M. Rhodes, MD, MSCE; and Krish Patel, MD

ByJoanna M. Rhodes, MD, MSCE,Krish Patel, MD

December 31st 2025

Drs Rhodes and Patel highlight how the chronic lymphocytic leukemia treatment paradigm continues to evolve with advances in targeted therapy.

Future Outlooks in the Treatment of R/R DLBCL

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

February 27th 2024

Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.

Additional Data Updates from ASH 2023

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

February 20th 2024

Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.

Treatment Sequencing of Later Line Therapies in R/R DLBCL

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

February 20th 2024

With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.

R/R DLBCL: Safety Considerations for Bispecific Antibodies

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

February 13th 2024

A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.

Bispecifics for Third Line Therapy of R/R DLBCL

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

February 13th 2024

Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.

Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

February 6th 2024

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

February 6th 2024

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

January 30th 2024

Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.

Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

January 30th 2024

Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.

The Role of CAR T-Cell Therapy in R/R DLBCL

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

January 29th 2024

Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.

Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

January 29th 2024

Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.

Tafasitamab and Lenalidomide for R/R DLBCL

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

January 16th 2024

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

Treatment Selection in Second Line R/R DLBCL

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

January 16th 2024

Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.

Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

January 16th 2024

A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.

Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

BySonali Smith, MD,Krish Patel, MD,Lorenzo Falchi, MD,Elizabeth Budde, MD, PhD,Haifaa Abdulhaq, MD,Jason Westin, MD

December 19th 2023

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.

Non-Hodgkin’s Lymphoma: New Medicines that Address Patient Needs

ByKrish Patel, MD

August 14th 2023

Krish Patel, MD, discusses the latest advances in the treatment of non-Hodgkin’s lymphoma and how fixed-duration treatment options can improve the overall patient experience.

Dr. Patel on Factors to Consider When Treating Relapsed/Refractory Follicular Lymphoma

ByKrish Patel, MD

September 29th 2022

Krish Patel, MD, discusses the factors to consider when treating patients with relapsed and/or refractory follicular lymphoma.

Dr. Patel on Emerging Therapeutic Strategies in MCL

ByKrish Patel, MD

March 20th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses emerging therapeutic strategies and ongoing research in mantle cell lymphoma (MCL).

Dr. Patel Discusses Zanubrutinib in MCL

ByKrish Patel, MD

March 11th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses zanubrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Patel on Induction in Patients With Mantle Cell Lymphoma

ByKrish Patel, MD

February 19th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).

Dr. Patel on Ibrutinib in Real-World Setting Versus Clinical Trials

ByKrish Patel, MD

February 13th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses a study looking at real-world benefit of BTK inhibitors versus what is seen in clinical trials for patients with mantle cell lymphoma.

Dr. Patel Discusses Promise of Acalabrutinib in MCL

ByKrish Patel, MD

January 15th 2019

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses the promise of acalabrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Patel on Differences Between BTK Inhibitors in MCL

ByKrish Patel, MD

January 9th 2019

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses differences between BTK inhibitors in mantle cell lymphoma (MCL).

Dr. Patel on Induction Therapy With Bendamustine and Rituximab in MCL

ByKrish Patel, MD

December 11th 2018

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses induction therapy with bendamustine and rituximab (Rituxan; BR) in the treatment of patients with mantle cell lymphoma (MCL).